Duke of Gloucester opens Vindon headquarters in Rochdale, UK
Facilities to support growth plans
Vindon Scientific operates in several markets, including the healthcare, pharmaceutical, life sciences, food sectors and heritage sectors. It is a leading supplier of environmental control products and services for the management of temperature, humidity and light, where controlled environment storage is needed.
The Duke of Gloucester formally opened the new state-of-the-art premises and met Vindon’s directors who gave him a tour of the 29,000ft2 facilities, which are now fully operational and geared up to support the company's ambitious growth plans.
His Royal Highness was shown the specialist products and services that Vindon provides, including stability storage, ultra-low temperature facilities and cryogenic sample storage for stem cells.
‘It was good to see that companies such as Vindon were investing in future technologies,’ he said.
Patrick Jackson, business development director at Vindon, added: ‘We were delighted to welcome the Duke of Gloucester to our new home here at Kingsway. To be chosen to represent this area of Rochdale is a great honour. We’re pleased to see continued investment in the Business Park, which will encourage more new ventures to join us.’
The Lord Lieutenant of Greater Manchester, the Mayor of Rochdale, Zulfiqar Ali, and leader of Rochdale Council, Irene Davidson, accompanied HRH Duke of Gloucester on his visit.
You may also like
Manufacturing
IMA Life-Sharp Sterile Manufacturing partnership strengthened with aseptic technology facility
Sharp's expanded facility in Massachusetts will include the installation of a fully automated IMA Life isolated filling line for Ready-To-Use (RTU) vials, addressing demand for US-based aseptic fill-finish services
Manufacturing
Cellistic launches three new iPSC-based GMP platforms to advance immuno-oncology and regenerative therapies
The three new iPSC-derived GMP manufacturing platforms, Echo-T, Echo-Cardio and Echo-Endothelial, expand the company’s Echo portfolio and are designed to improve scalability and manufacturability across immuno-oncology and regenerative medicine programmes